Cingulate Inc. (NASDAQ:CING) Short Interest Down 95.8% in July

Cingulate Inc. (NASDAQ:CING) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 8,300 shares, a drop of 95.8% from the July 15th total of 199,100 shares. Based on an average trading volume of 54,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the shares of the company are sold short.

Cingulate Stock Performance

Shares of CING stock opened at $2.85 on Tuesday. The business has a fifty day moving average of $0.55 and a 200 day moving average of $0.93. Cingulate has a 1 year low of $1.82 and a 1 year high of $187.20.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.